Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Trump's former FDA commissioner criticized the current administration's approach to measles and infant formula at #STATBreakthrough ...
In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.
The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...
The company's new CEO joined the team last year from Medtronic, one of the largest medical device companies in the world.
Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...
Mattiedna Johnson was a nurse, laboratory technician, and medical researcher who revolutionize modern antibiotic treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback